anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicinal formula for treating intestinal obstruction. Each dose of medicine is prepared from the following medicinal materials by mass: 20 to 30 g of rheum officinale, 10 to 15 g of fructus aurantii immaturus, 10 to 15 g of rhizoma corydalis, 10 to 15 g of radix paeoniae alba, 5 to 10 g of liquoric root, 15 to 20 parts of anhydrous sodium sulphate, 10 to 20 g of officinal magnolia bark, 10 to 20 g of agilawood, 10 to 15 g of green tangerine peel and 20 to 30 g of oven earth; the medicinal materials are decocted and are taken twice or three times a day. Through reasonable matching of various components, the traditional Chinese medicinal formula can clean intestines and the stomach, promote circulation of water valley, and stimulate colonic wall to cause intestinal contraction and secretion increment, so that colon contents are defecated easily, and effects of purgating and defaecating are achieved. After toxin in a body is cleaned, the internal environment of the body is purified, so that the body of a patient recovers quickly. One treatment period is one week, the recovery rate of one treatment period is 72 percent, and the recovery rate of two treatment periods can reach 83 percent. In a process of taking the traditional Chinese medicine by the patient, no untoward effect is caused.
The invention discloses a bee venom permeating agent, a preparation method of the bee venom permeating agent, a preparation and an application. Raw materials of the bee venom comprise alcohol, wasp bee venom powder, old working bee of live wasp and picadura. After the steps of the bee venom original fluid preparation, the worker bee material preparation, the mother liquid preparation and the preparation, the bee venom permeating agent is obtained. The bee venom permeating agent can be directly smeared on the pain areas caused by rheumatism, scapulohumeral periarthritis and arthritis. The bee venom permeating agent rapidly permeates through the histocyte, the blood capillary and other areas of the pain areas through the skin clearance. The effect is direct, the curative effect is rapid, and the efficacy of the bee venom especially the wasp bee venom is fully utilized. Accordingly, the current problems of the low efficacy of the wine steeping with the old worker bee and non-drinkers are thoroughly solved.
The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
Metoprolol succinate is a beta 1-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended-release tablets. Metoprolol Succinate Extended-Release Tablets USP have been formulated to provide a controlled and predictable release of metoprolol for once-daily administration. The tablets comprise a multiple unit system containing metoprolol succinate in a multitude of controlled release granules. Each granule acts as a separate drug delivery unit and is designed to deliver metoprolol continuously over the dosage interval. The tablets contain 95 and 190 mg of metoprolol succinate equivalent to 100 and 200 mg of metoprolol tartrate, USP, respectively. Its chemical name is (±)1-(isopropylamino)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol succinate (2:1) (salt). Its structural formula is: 

Metoprolol succinate, USP is a white crystalline powder with a molecular weight of 652.8. It is freely soluble in water; soluble in methanol; sparingly soluble in ethanol; slightly soluble in dichloromethane and 2-propanol; practically insoluble in ethyl-acetate, acetone, diethylether and heptane. Inactive ingredients: colloidal silicon dioxide, crospovidone, ethylcellulose, ethylene glycol and vinyl alcohol graft copolymer, glycerol monocaprylocaprate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, triethyl citrate. Contains no ingredient made from a gluten-containing grain (wheat, barley, or rye).

Meets USP Dissolution Test 7.
Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses \<10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive CD19/CD22-CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of CD19/CD22-CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
The presence or quantity of a selected subset of cells, which is part of a subpopulation of a mixed cell population, is determined by a method in which a detectable reporter substance is uniformly incorporated into substantially all cells of the subpopulation containing the subset of interest. The subset of interest is then affinity-separated by incubating a test sample of the mixed cell population containing the labeled subpopulation with a specific binding substance which selectively binds to characteristic determinants of the cell subset of interest. Occurence of the reporter substance in the separated fraction is then detected, and correlated to a predetermined standard to determine the presence or quantity of the subset of interest within the cell population. According to another aspect of the invention a method is provided for quantitating two or more selected subsets of cells within a subpopulation of a mixed cell population. After labeling, the entire subpopulation is affinity-separated from the mixed cell population, and occurence of the reporter substance in the separated fraction is detected. Next, subsets of interest within the subpopulation are affinity-separated as described above, and the level of detected reporter substance in each subset is compared to the level detected in the entire subpopulation. According to further aspects of the invention test kits are provided for performing the above-described methods.
Breast cancer-related lymphedema (BCRL) remains a challenging condition impacting function and quality of life. Complete decongestive therapy (CDT) is the current standard of care, necessitating a comprehensive review of its impact. This paper presents a systematic review (SR) of SRs on CDT's efficacy in BCRL, and the components of manual lymph drainage (MLD) and exercise. A literature search yielded 13 SRs published between January 2018 and March 2023 meeting inclusion criteria, with varied quality ratings based on the AMSTAR II. A sub-analysis of CDT investigated the within group effect size estimations on volume in different stages of lymphedema. While a moderate quality SR indicated support for CDT in volume reduction, other SRs on the topic were of critically low quality. Larger effect sizes for CDT were found for later stage BCRL. The impact of MLD as a component of CDT demonstrated no additional volume benefit in a mix of moderate to low quality SRs. Similarly, exercise's role in volume reduction in CDT was limited, although it demonstrated some benefit in pain and quality of life. A rapid review of trials published January 2021-March 2023 reinforced these findings. Variability in CDT delivery and outcomes remained. These findings underscore the need to standardize staging criteria and outcome measures in research and practice. Future research should focus on refining interventions, determining clinically important differences in outcomes, and standardizing measures to improve evidence-based BCRL management. Current evidence supports CDT's efficacy in BCRL. MLD and exercise as components of CDT have limited support for volume reduction.
Uncontrollable bleeding caused by severe trauma is life-threatening. Therefore, it is of great significance to develop hemostatic materials that meet the rapid hemostasis of wounds. In this study, a water-triggered shape memory carboxylated cellulose nanofiber/sodium alginate/montmorillonite (CNSAMMTCa) composite hemostatic sponge was prepared, which can promote coagulation by concentrating the blood and activating intrinsic pathway. The anisotropic three-dimensional porous structure formed by directional freeze-drying technology improved the performance of composite sponges which showed good prospects in rapid hemostasis. The results showed that CNSAMMTCa composite sponge had good porous structure, water absorption ability, cytocompatibility and blood cell aggregation capacity. Simultaneously, we confirmed that CNSA3MMT2Ca has best coagulation performance in the mouse censored bleeding model and liver rupture bleeding model. Therefore, CNSAMMTCa composite hemostatic sponge is a safe and efficient rapid hemostatic material which is expected to become an alternative material for clinical hemostatic materials.
The present invention relates to a medicinal granule for relaxing and activating the tendons, which can be used for limb-kinetic apraxia after limb fracture healing. The present invention is characterized in that the medicinal granule is prepared from medicines of the following parts by weight: 8 to 12 parts of suberect spatholobus, 8 to 12 parts of polygoni cuspidati, 8 to 12 parts of rhizoma drynariae, 8 to 12 parts of twotoothed achyranthes root, 8 to 12 parts of herba lycopodli, 8 to 12 parts of Chinese starjasmine stem, 8 to 12 parts of pawpaw, 8 to 12 parts of cassia twig and 8 to 12 parts of olibanum. The preparation method for the medicinal granule for relaxing and activating the tendons comprises the following procedures: each raw material is weighed and is reserved. The raw materials of the proportion by weight are added with water and decocted twice. In each time, the amount of water added is preferably to just submerge the medicines. The decoction liquid at both times is merged. The decoction liquid in both times is filtered and concentrated into an extract of which the specific weight is 1.35. the extract is added with ethanol of 90% to 95% for ethanol deposition and concentration. The extract is dried at 45 to 50 DEG C, and a dry extract is prepared. The dry extract is broken into fine powder, added with ethanol used as an adhesive, added with starch used as a loading agent, and pressed into granules or tablets. The oral medicinal liquid is taken twice a day, and 5 to 7 preparations form one curative course. Symptoms can be eliminated by one course, and the medicine taking is stopped. The present invention has the advantages of obvious effect, short curative course and durative curative effect.
Interoception refers to the ability to sense internal bodily sensations. Research suggests that dysfunctions in interoception may be implicated in the transition to chronic pain, however, little work has examined interoceptive ability in pain states. Therefore, this systematic review aimed to assess whether interoception is altered in individuals experiencing pain. Following a systematic search of 4 electronic databases from inception to February 2023, 28 studies were included. Outcomes of interoceptive accuracy, interoceptive sensibility, and interoceptive awareness were meta-analysed. The risk of bias was assessed, and the certainty of the evidence was evaluated. Meta-analyses indicated that those with chronic pain display reduced interoceptive accuracy and increased interoceptive sensibility. Subgroup analyses indicated that the change in interoceptive sensibility is dependent on the measure used, with those with chronic pain scoring higher on measures focusing on attention to bodily sensations, while also scoring lower on emotional reactivity. No difference in interoceptive awareness was observed between individuals with chronic pain and pain-free controls. Only one study was found that measured interoception in those experiencing acute pain, while another study recruited those experiencing recurrent pain. These findings suggest that while those with chronic pain self-report as more interoceptively aware, they are less accurate at detecting internal bodily signals. Further research investigating domains of interoception in those experiencing acute and recurrent pain is needed. Data should be interpreted with caution as the certainty of evidence was very low for all completed analyses. This review was registered on the PROSPERO International Prospective Register of Systematic Reviews (Registration ID = CRD42022318843). PERSPECTIVE: This review considered the relationship between interoception and pain and found that an individual's ability to accurately sense internal signals is decreased in those with chronic pain, despite them reporting being more aware of internal sensations. However, there remains little research examining interoception in non-chronic pain states.
Participants will receive 1-month access to the Kurbo digital program and the PolyRules! app.
PURPOSE:To obtain an antiallergic agent capable of preventing or treating allergy, especially, infant allergy. CONSTITUTION:This antiallergic preparation is composed of glutamine. The preparation has the form of a tablet or a nutrient composition, e.g. a prepared milk for an infant. The glutamine may be any one of a free-type glutamine, a peptide-type glutamine or a hydrolysate of natural products. The compounded amount is, preferably, >=30mg wt.% in terms of solid.
PURPOSE:A drug for coccidiosis of domestic fowls, containing an antibiotic bundlin A as an active constituent, and having a powerful anticoccidial action, and usable continuously for a long term with low toxicity. CONSTITUTION:A drug for coccidiosis of domestic fowls, containing an antibiotic bundlin A as an active constituent, and capable of effectively protecting the domestic fowls from coccidiosis. The drug is used orally and incorporated in an amount of about 0.0005-0.05wt% based on a feed or drinking water, and administered to the domestic fowls. The atibiotic substance is known as an antibiotic substance produced by Streptomyces griseofuscus nov sp. and proved to be the identical substance with the antibiotic substance lankacidin produced by Streptomyces zeolaceniger. Any of these substances may be used regardless of the produced strain unless the identity of the substances is spoiled.
The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
Composition comprises a copolymer of styrenic monomer and carboxylic diacid with ethylene unsaturation, and an active agent having a preventive and/or curative effect on a cutaneous signs of aging, where the active agent being agents having a restructuring effect of the cutaneous barrier, antiglycating agent, agents having an action of NO synthase inhibitor, active agent acting on the cutaneous microcirculation and/or active agent stimulating energy metabolism of cells, in a medium. An independent claim is included for a cosmetic process for the prevention and/or treatment of the cutaneous signs of aging, comprising applying the composition on the skin. ACTIVITY : Nootropic; Dermatological. MECHANISM OF ACTION : Melanogenesis modulator. The effect of the composition to modulate the melanogenesis was tested in human melanocytes and keratinocyte co-culture. The result showed that the composition exhibited IC50 value of 60 mu M.
A conjugate comprises a biologically active molecule (e.g. protein, peptide, nucleic acid, oligosaccharide, polysaccharide or lipid) and a 5-fluoro-5-deoxypentose or a 3-fluoro-3-deoxypentose. The 5- or 3- fluoro deoxy pentose may be 5- or 3- 18F and be useful for PET imaging. The pentose may be an aldodeoxypentose; it may be a 2-deoxypentose; it may be a may be a ribose, xylose, arabinose, lyxose, ribulose or xylulose. The conjugate may be formed through an oxime, hydrazone or thiosemicarbazone linkage. The pentose may be a 3,5-difluoro-3,5-dideoxypentose; it may be 5-fluoro-2,5-dideoxyribose. The pentose may be substituted with, for example, alkyl, amino and alkoxy groups. Conjugates [18F]-5-fluoro-5-deoxyribose and glutathione were prepared.
The invention provides siRNA for inhibiting Apo (a) gene expression and a composition thereof, belonging to the technical field of biological medicine. siRNA for inhibiting Apo (a) gene expression and a composition thereof belong to the technical field of biological medicines. The siRNA of the present invention comprises a sense strand and an antisense strand; wherein the antisense strand comprises at least 17 continuous nucleotides with a nucleotide sequence difference of not more than 4 nucleotides from any one of SEQ ID NO. 2-SEQ ID NO. 45, SEQ ID NO. 138-SEQ ID NO. 179, and the antisense strand has a length of 17-30 nucleotides; the sense strand is 17-30 nucleotides in length and is at least partially complementary to the antisense strand. The siRNA and the pharmaceutical composition containing the siRNA can prevent or treat diseases related to the Apo (a) gene through inhibiting the Apo (a) gene. In addition, the siRNA and the pharmaceutical composition containing the siRNA provided by the invention have good stability, satisfactory cytotoxicity and immunostimulation and safe use.
An isolated Bifidobacteria DNA fragment comprises nucleic from sequence ID No.1, sequence ID No.2 or sequence ID No.3.  A protein having sequence ID No.4, sequence ID No.5, sequence ID No. 6, sequence ID No, 7, sequence ID No. 8 or sequence ID No. 9 is also disclosed as are DNA fragments comprising sequence ID No. 10 or 11 and proteins encoded thereby.  A two-component signal transduction system comprises a gene encoding sequence ID No. 4 and a gene encoding sequence ID No. 5, a gene encoding sequence ID No 6 and a gene encoding sequence ID No. 7 or a gene encoding sequence ID No.8 and a gene encoding sequence ID No. 9.  The Bifidobacteria may be Bifidobacterium infantis UCC35624.
Benign liver lesions are among the most commonly diagnosed abnormalities in liver imaging. They are often discovered incidentally during routine examinations or imaging conducted for unrelated reasons. These can be solid lesions, such as hemangiomas, focal nodular hyperplasia, hepatic adenomas, or cystic lesions. Recent advancements in MRI technology, particularly with hepatocyte-specific contrast agents, have enhanced the characterization of these lesions, reducing the reliance on invasive tissue sampling. Nevertheless, tissue sampling retains a crucial role in the evaluation of indeterminate lesions or those with malignant potential. While most benign liver lesions are asymptomatic, some can become symptomatic, causing discomfort, pain, or bleeding, particularly if the lesion is large. A deep understanding of the molecular underpinnings of the lesions is crucial for tailoring patient management strategies, particularly in distinguishing lesions that require surgical intervention from those that can be monitored. For instance, the molecular subclassification of hepatic adenomas has provided mechanistic insights and identified certain subtypes that are at higher risk of malignancy. Most benign liver lesions can be safely monitored; however, in patients with cirrhosis or a known primary malignancy, a high index of suspicion for cancer is required. It is crucial to carefully evaluate any liver lesion identified in these patients to ensure that indeterminate lesions are not overlooked. Effective management of benign liver lesions involves a multidisciplinary team, including hepatologists, surgeons, and radiologists, ensuring a comprehensive and individualized approach to patient care. This review outlines the clinical presentation of common benign liver lesions, providing a diagnostic and management framework. Emphasis is placed on a personalized approach to minimize patient distress and optimize outcomes by leveraging imaging advancements and multidisciplinary collaboration.
Pharmaceutical and veterinary compositions comprise non-toxic, pharmaceutically acceptable, inert diluents or carriers and at least one compound of general formula <FORM:0870469/VI/1> wherein R1 and R2 which may be the same or different represent hydrogen or alkyl radicals optionally substituted by hydroxy or dialkylamino radicals, or R1 and R2, together with the adjacent nitrogen atom form a saturated heterocyclic ring, e.g. a piperidine, morpholine or hexamethyleneimine radical and wherein the ring (A) may optionally bear one or more substituents which may be the same or different selected from lower alkyl, lower alkoxy, lower alkylthio, halogen, nitro, carboxy, carbalkoxy, acyl, alkylaminosulphonyl and acylamino radicals or a non-toxic acid addition salt thereof, the term "lower" denoting radicals containing not more than 6 carbon atoms.  The compositions may be in the form of tablets, capsules, dispersable powders, mixtures with animal foodstuffs and premixes for addition thereto, salt licks and aqueous and oily suspensions for oral and parenteral use.  They may optionally contain "trace elements," e.g. cobalt, manganese, copper and iodine and known anthelmintic drugs, e.g. piperazine, phenothiazine, hexachloroethane, cyanacethydrazide, copper sulphate or nicotine sulphate.
Fibrillary glomerulonephritis (FGN) is a rare kidney disease typically affecting individuals in middle age, frequently presenting with advanced renal failure, proteinuria, and hypertension. FGN can be associated with autoimmune diseases, hepatitis C infection, and malignancies. Its exact pathogenesis remains elusive, and the exact role of DnaJ homolog subfamily B member 9 is yet to be determined. On renal biopsy, FGN exhibits distinctive Congo-red-negative, nonbranching fibrils, approximately 20 nm in diameter. DnaJ homolog subfamily B member 9 immunohistochemical staining has become a gold standard for diagnosis. Atypical variants exist, including congophilic, monotypic, and crescentic FGN, highlighting the disease's heterogeneity. Treatment with immunosuppression, including rituximab, has shown variable success, with no standard therapy established. FGN often leads to end-stage kidney disease, with a median progression time of 2-4 years postdiagnosis. Kidney transplantation is a viable option for FGN-related end-stage kidney disease, but recurrence in transplanted kidneys is not rare.
Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.